Biocept, Inc. (NASDAQ: BIOC) Starts Presentation at 30th Annual ROTH Conference
Biocept (NASDAQ: BIOC) is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. By leveraging its proprietary liquid biopsy technology, the company provides physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept’s patented Target Selector™ liquid biopsy technology platform identifies and analyzes tumor-associated molecular markers in both circulating tumor cells and in circulating tumor DNA. The platform has demonstrated the ability to identify cancer mutations and alterations to notify physicians about a patient’s disease and therapeutic options. For more information, visit the company’s website at www.biocept.com. About…
